(Q39389987)

11 September 2017

title

Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs (English)

1 reference

11 September 2017

Efficacy of Eletriptan in Migraineurs With Persistent Poor Response to Nonsteroidal Anti‐inflammatory Drugs (English)

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

14 March 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

14 March 2024

3

Shuu-Jiun Wang

1 reference

11 September 2017

1

Yook-Chin Chia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511275

14 March 2024

author name string

Shih-Hui Lim

2

1 reference

11 September 2017

Jean Denaro

5

1 reference

11 September 2017

Jayasena Hettiarachchi

6

1 reference

11 September 2017

Y. M. Cheong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511275

14 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14511275

14 March 2024

publication date

1 October 2003

1 reference

full work available at URL

11 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1526-4610.2003.03190.x

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1526-4610.2003.03190.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

https://onlinelibrary.wiley.com/doi/full-xml/10.1046/j.1526-4610.2003.03190.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

14 March 2024

1 reference

11 September 2017

volume

43

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

984-990

1 reference

Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

The role of headache-related disability in migraine management: implications for headache treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

Migraine in the United States: epidemiology and patterns of health care use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

Guidelines for controlled trials of drugs in migraine: second edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03190.X

Treatment of acute migraine attack with diclofenac sodium: a double-blind study

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Effectiveness of Oral Diclofenac in the Acute Treatment of Common Migraine Attacks: A Double-Blind Study Versus Placebo

14 March 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Treatment of acute migraine attack: ibuprofen and placebo compared

14 March 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo

14 March 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine

14 March 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial

14 March 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study

14 March 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Diclofenac-potassium in migraine: a review

14 March 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Management of migraine: an algorithmic approach

14 March 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Migraine--current understanding and treatment

14 March 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society

14 March 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial

14 March 2024

17

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

The cost effectiveness of stratified care in the management of migraine

14 March 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

14 March 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

14 March 2024

22

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain

14 March 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.

14 March 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

14 March 2024

25

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

14 March 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

14 March 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs

14 March 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan

14 March 2024

36

1 reference

https://api.crossref.org/works/10.1046/J.1526-4610.2003.03190.X

14 March 2024

Identifiers

1 reference

release_75grt5okjzhulcmsybaew24rgy

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/75grt5okjzhulcmsybaew24rgy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference